Castañeda, Kelly M.
Sidorenkov, Grigory
Mourits, Marian J. E.
van der Vegt, Bert
Siebers, Albert G.
Vermeulen, Karin M.
Schuuring, Ed
Wisman, G. Bea A.
de Bock, Geertruida H.
Funding for this research was provided by:
Departamento Administrativo de Ciencia, Tecnología e Innovación (PhD call 860)
ZonMw (531002021)
Article History
Received: 4 March 2023
Accepted: 22 November 2023
First Online: 30 November 2023
Declarations
:
: Informed consent was obtained from all participants. The Lifelines study complies with the principles of the Declaration of Helsinki and has received approval from the Medical Ethics Committee of the University Medical Center Groningen, the Netherlands (no. 2007/152).
: Not applicable.
: Bert van der Vegt reports scientific advisory board/consultancy (on request): Visiopharm, Philips, MSD/Merck, Daiichi-Sankyo/AstraZeneca; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. All honoraria to UMCG. All unrelated to the current manuscript.Ed Schuuring reports lectures for Bio-Rad, SeraCare, Novartis, Roche, Biocartis, Illumina, Lilly, Janssen Cilag, Pfizer, AstraZeneca and Agena Bioscience; consultant in advisory boards for MSD/Merck, GSK, AstraZeneca, Astellas Pharma, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Biocartis, Illumina, Agena Bioscience, Janssen Cilag (Johnson & Johnson), Diaceutics, CC Diagnostics; and received research grants from Pfizer, Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bioscience, BMS, Bio-Rad, Roche, Boehringer Ingelheim (honoraria paid to UMCG account). All unrelated to the current manuscript.The rest of the authors declare that they have no competing interests.